Last updated on October 2018

Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma


Brief description of study

A randomized, multicenter, double-blind, placebo- controlled parallel-group study to determine the efficacy and safety of QAW039, compared with placebo, when added to standard-of-care (SoC) asthma therapy in adult and adolescent ( 12 years) patients with uncontrolled asthma with respect to change from baseline in forced expiratory volume in 1 second (FEV1) at the end of 12 weeks of treatment.

Clinical Study Identifier: NCT03226392

Contact Investigators or Research Sites near you

Start Over

Novartis Pharmaceuticals

Novartis Investigative Site
Pittsburgh, PA United States
3.77miles
  Connect »